Breast sentinel lymph node dissection before preoperative chemotherapy

Archives of Surgery

Volumn 143, Issue 7, 2008, Pages 692-699

  Grube, Baiba J ^a   Christy, Carla J ^a   Black, Dalliah ^a   Martel, Maritza ^a   Harris, Lyndsay ^a   Weidhaas, Joanne ^a   DiGiovanna, Michael P ^a   Chung, Gina ^a   Abu Khalaf, Maysa Mahmoud ^a   Miller, Kenneth D ^a   Higgins, Susan A ^a   Philpotts, Liane ^a   Tavassoli, Fattaneh A ^a   Lannin, Donald R ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SENTINEL LYMPH NODE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREOPERATIVE CARE; PROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY;

EID: 47849114861     PISSN: 00040010     EISSN: 15383644     Source Type: Journal    
DOI: 10.1001/archsurg.143.7.692     Document Type: Article

References (75)

1. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220(3):391-401.
2. Grube BJ, Giuliano AE. The current role of sentinel node biopsy in the treatment of breast cancer. Adv Surg. 2004;38:121-166.
3. Lyman GH, Giuliano AE, Somerfield MR, et al; American Society of Clinical Oncology. American Society of Clinical Oncology Guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005; 23(30):7703-7720.
4. Sabel MS, Zhang P, Barnwell JM, Winston JS, Hurd TC, Edge SB. Accuracy of sentinel node biopsy in predicting nodal status in patients with breast carcinoma. J Surg Oncol. 2001;77(4):243-246.
5. Stitzenberg KB, Calvo BF, Iacocca MV, et al. Cytokeratin immunohistochemical validation of the sentinel node hypothesis in patients with breast cancer. Am J Clin Pathol. 2002;117(5):729-737.
6. Turner RR, Ollila DW, Krasne DL, Giuliano AE. Histopathologic validation of the sentinel lymph node hypothesis for breast carcinoma. Ann Surg. 1997;226 (3):271-276.
7. Weaver DL, Krag DN, Harlow SP, O'Connell M. Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma. Cancer. 2000;88(5):1099-1107.
8. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24(13):2019-2027.
9. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(3):188-194.
10. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17(2):460-469.
11. Kuerer HM, Sahin A, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230(1): 72-78.
12. Kuerer HM, Hunt KK, Newman LA, Ross MI, Ames FC, Singletary SE. Neoadjuvant chemotherapy in women with invasive breast carcinoma: conceptual basis and fundamental surgical issues. J Am Coll Surg. 2000;190(3):350-363.
13. Veronesi U, Paganellli G, Viale G, et al. Sentinel-lymph node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol. 2006;7(12):983-990.
14. Harris LN, Kaelin CM, Bellow JR, Winer ER. Preoperative therapy for operable breast cancer. In: Harris JR, Lippman ME, Morrow M, eds. Disease of the Breast. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004:929-943.
15. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16(8): 2672-2685.
16. Breslin TM, Cohen L, Sahin A, et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000;18(20):3480-3486.
17. Nason KS, Anderson BO, Byrd DR, et al. Increased false negative sentinel node rates after preoperative chemotherapy for invasive breast carcinoma. Cancer. 2000; 89(11):2187-2194.
18. Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol. 2000;24 (9):1266-1272.
19. Tafra L, Verbanac KM, Lannin DR. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg. 2001;182(4):312-315.
20. Haid A, Tausch C, Lang A, et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer. 2001;92(5):1080-1084.
21. Fernández A, Cortés M, Benito E, et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy. Nucl Med Commun. 2001;22(4):361-366.
22. Miller AR, Thomason VE, Yeh I-T, et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol. 2002;9(3):243-247.
23. Stearns V, Ewing CA, Slack R, Penannen MF, Hayes DF, Tsangaris TN. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla for inflammatory breast cancer. Ann Surg Oncol. 2002; 9(3):235-242.
24. Brady EW. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J. 2002;8(2):97-100.
25. Julian TB, Dusi D, Wolmark N. Sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg. 2002;184(4):315-317.
26. Piato JRM, Barros ACSD, Pincerato KM, Sampaio APQ, Pinotti JA. Sentinel lymph node biopsy in breast cancer after neoadjuvant chemotherapy: a pilot study. Eur J Surg Oncol. 2003;29(2):118-120.
27. Schwartz GF, Meltzer AJ. Accuracy of axillary sentinel lymph node biopsy following neoadjuvant (induction) chemotherapy for carcinoma of the breast. Breast J. 2003;9(5):374-379.
28. Balch GC, Mithani SK, Richards KR, Beauchamp RD, Kelley MC. Lymphatic mapping and sentinel lymphadenectomy after preoperative therapy for stage II and III breast cancer. Ann Surg Oncol. 2003;10(6):616-621.
29. Mamounas EP. Sentinel lymph node biopsy after neoadjuvant systemic therapy. Surg Clin North Am. 2003;83(4):931-942.
30. Reitsamer R, Peintinger F, Rettenbacvher L, Prokop E. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy. J Surg Oncol. 2003;84(2):63-67.
31. Patel NA, Piper G, Patel JA, Malay MB, Julian TB. Accurate axillary nodal staging can be achieved after neoadjuvant therapy for locally advanced breast cancer. Am Surg. 2004;70(8):696-700.
32. Lang JE, Esserman LJ, Ewing CA, et al. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. J Am Coll Surg. 2004;199(6):856-862.
33. Jones JL, Zabicki K, Christian RL, et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. AmJ Surg. 2005; 190(4):517-520.
34. Shen J, Gilcrease MZ, Babiera GV, et al. Feasibility and accuracy of sentinel lymph nodes biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases. Cancer. 2007;109(7):1255-1263.
35. Newman EA, Sabel MS, Nees AV, et al. Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol. 2007;14(10):2946-2952.
36. Lee S, Kim EY, Kang SH, et al. Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients. Breast Cancer Res Treat. 2007;102(3):283-288.
37. Kinoshita T. Sentinel lymph node biopsy is feasible for breast cancer patients after neoadjuvant chemotherapy. Breast Cancer. 2007;14(1):10-15.
38. Greene F. Breast cancer. In: Greene F, Page D, Fleming I, et al, eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002:221-240.
39. Sabel MS, Schott AF, Kleer CG, et al. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg. 2003;186(2):102-105.
40. Schrenk P, Hochreiner G, Fridrik M, Wayand W. Sentinel node biopsy performed before preoperative chemotherapy for axillary lymph node staging in breast cancer. Breast J. 2003;9(4):282-287.
41. Ollila DW, Neuman HB, Sartor C, Carey LA, Klauber-DeMore N. Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. Am J Surg. 2005;190(3):371-375.
42. van Rijk MC, Niewig OE, Rutgers EJT, et al. Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection. Ann Surg Oncol. 2006;13(4):475-479.
43. Cox CE, Cox JM, White LB, et al. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann Surg Oncol. 2006;13(4):483-490.
44. Lannin DR, Grube B, Black DM, Ponn T. Breast tattoos for planning surgery following neoadjuvant chemotherapy. Am J Surg. 2007;194(4):518-520.
45. Black DM, Christy CJ, Grube BJ, et al. Intraoperative injection of 99m-technetium sulfur colloide for breast sentinel lymph node biopsy. Paper presented at: 88th Annual Meeting of the New England Surgical Society; September 29, 2007; Burlington, VT.
46. Wong JH, Cagle LA, Morton DL. Lymphatic drainage of the skin to a sentinel lymph node in a feline model. Ann Surg. 1991;214(5):637-641.
47. Borgstein PJ, Pijpers R, Comans EF, van Diest PJ, Boom RP, Meijer S. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg. 1998;186(3):275-283.
48. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med. 1998;339(14):941-946.
49. O'Hea BJ, Hill AD, El-Shirbiny AM, et al. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg. 1998;186(4):423-427.
50. Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (>5 cm) invasive breast cancer. Ann Surg Oncol. 2001; 8(9):688-692.
51. Kinoshita T, Takasugi M, Iwamoto E, Akashi-Tanaka S, Fukutomi T, Terui S. Sentinel lymph node biopsy examination for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy. Am J Surg. 2006;191(2):225-229.
52. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93(5):539-546.
53. Baslaim MM, Al-Malik OA, Al-Sobhi SS, et al. Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. Am J Surg. 2002;184(4): 299-301.
54. Neuman H, Carey LA, Ollila DW, et al. Axillary lymph node count is lower after neoadjuvant chemotherapy. Am J Surg. 2006;191(6):827-829.
55. Tavassoli FA. Pathology of the Breast. Stamford, CT: Appleton & Lange; 1999.
56. Sharkey FE, Addington SL, Fowler LJ, Page CP, Cruz AB. Effects of preoperative chemotherapy on the morphology of resectable breast carcinoma. Mod Pathol. 1996;9(9):893-900.
57. Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-18. Cancer. 2002;95(4):681-695.
58. Aktepe F, Kapucuoglu N, Pak I. The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. Histopathology. 1996;29(1):63-67.
59. Tafra L, Lannin DR, Swanson MS, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue. Ann Surg. 2001;233(1):51-59.
60. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 25(28):4414-4422.
61. Ogston KN, Miller ID, Hutcheon AW, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320-327.
62. Khan A, Sabel MS, Nees AV, et al. Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol. 2005;12(9):697-704.
63. Mauriac L, MacGrogan G, Avril A, et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124 month median follow-up (IBBGS). Ann Oncol. 1999;10(1):47-52.
64. Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial. Semin Surg Oncol. 2001;20(3):230-237.
65. Lucci A, McCall LM, Beitsch PD, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657-3663.
66. Guenther JM, Hansen NM, DiFronzo LA, et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg. 2003; 138(1):52-56.
67. Fant JS, Grant MD, Knox SM, et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection. Ann Surg Oncol. 2003;10(2):126-130.
68. Jeruss JS, Winchester DJ, Sener SF, et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol. 2005;12(1):34-40.
69. Hwang RF, Gonzalez-Angulo AM, Buchholz TA, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary lymph node dissection. Cancer. 2007; 110(4):723-730.
70. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009.
71. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
72. Perou CM, Jeffrey SS, van de Rijn M, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A. 1999;96(16):9212-9217.
73. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.
74. Hayes DF, Thor AD, Dressler LG, et al. Her2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007;357(15):1496-1506.
75. Huang EH, Strom EA, Perkins GH, et al. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys. 2006;66(2):352-357.